RDs find themselves counseling patients who are curious or take these medications and often are peppered with questions about their actions, side effects, and implications for short- and long-term use
Dulaglutide | Drugs | BNF - NICE
By Diabetes Type: Type 1 Growth Accelerates Through Technology Adoption Type 2 conditions comprise 90.78% of Mexico diabetes care drugs and devices market size because of sheer prevalence, yet type 1 is projected to post a 4.82% CAGR through 2031
Always consult with your healthcare provider to make sure your treatment plan is right for you
If you are interested, monitoring your blood sugar regularly can provide valuable insights into how well the medication works
The combined primary endpoint of death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke occurred in 569 (6.5%) of patients in the semaglutide group versus 701 (8.0%) of patients in the placebo group, yielding a significant hazard ratio of 0.8 for a 20% relative risk reduction